scholarly journals Shared decision making for men facing prostate cancer treatment: a systematic review of randomized controlled trials

2019 ◽  
Vol Volume 13 ◽  
pp. 1153-1174 ◽  
Author(s):  
Nahara Anani Martínez-González ◽  
Andreas Plate ◽  
Stefan Markun ◽  
Oliver Senn ◽  
Thomas Rosemann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Decision Making ◽  
Cancer Treatment ◽  
Randomized Controlled Trials ◽  
Shared Decision Making ◽  
Controlled Trials ◽  
Shared Decision ◽  
Prostate Cancer Treatment ◽  
Randomized Controlled

Shared-decision making in prostate cancer with clinical decision-support.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16576-e16576 ◽  
Author(s):  
Hermano Alexandre Lima Rocha ◽  
Irene Dankwa-Mullan ◽  
Sergio Ferreira Juacaba ◽  
Van Willis ◽  
Yull Edwin Arriaga ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Decision Making ◽  
Cancer Treatment ◽  
Shared Decision Making ◽  
Active Surveillance ◽  
Treatment Options ◽  
Clinical Decision ◽  
Treatment Decisions ◽  
Shared Decision ◽  
Prostate Cancer Treatment

e16576 Background: Shared decision-making is the process of deliberately interacting with patients who wish to make informed value-based choices, when there are no indicated best treatment options. Given the wide variation in prostate cancer treatment options, clinical decision-support systems (CDSS) may effectively support treatment decisions for patients with challenging risk-benefit profiles. However, limited data are available regarding CDSS in shared decision making. This study aimed to assess the alignment of CDSS therapeutic options with treatment received through a shared decision process. Methods: We identified patients with prostate cancer (Gleason Groups 1-5) who were engaged in shared treatment decision making, (from August–September 2018) at the Instituto do Câncer do Ceará, Brazil. IBM Watson for Oncology (WfO), a CDSS was used for the study. Treatment decisions were compared with WfO options (active surveillance, clinical trial, chemotherapy [CT], hormone therapy [HT], radiation [RT], brachytherapy [brachy], surgery and systemic therapy with GnRH suppression) and categorized as concordant (equivalent), partially concordant (a partial match), or discordant. Results: Concordance between WfO and shared treatment decisions was observed in 54% (26/48) of patients, partial concordance in 15% (7/48) and discordance in 31% (15/48). Most frequent treatments were RT+HT combination therapy (25%) and prostatectomy (21%). 8/15 (53%) discordant cases were due to patient preference for treatment over active surveillance. Patient preference for treatment over active surveillance was the most common reason (53%) for discordance. Conclusions: Variation in prostate cancer treatment exists. CDSS therapy options may be useful in quantifying and modifying unwarranted variations in prostate cancer treatment. Future studies are important for understanding reasons for variations. [Table: see text]

scholarly journals Correction to: The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Nahara Anani Martínez-González ◽  
Stefan Neuner-Jehle ◽  
Andreas Plate ◽  
Thomas Rosemann ◽  
Oliver Senn
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Decision Making ◽  
Cancer Screening ◽  
Usual Care ◽  
Shared Decision Making ◽  
Prostate Cancer Screening ◽  
Meta Analysis ◽  
Shared Decision

Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials

2014 ◽  
Vol 113 (5b) ◽  
pp. E119-E130 ◽  
Author(s):  
M. Diana van Die ◽  
Kerry M. Bone ◽  
Scott G. Williams ◽  
Marie V. Pirotta
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Soy Isoflavones ◽  
Controlled Trials ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document